This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Moertel, C. G. Articles by Hahn, R. G. Search for Related Content PubMed PubMed Citation Articles by Moertel, C. G. Articles by Hahn, R. G.

Sequential 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) and 5-Fluorouracil (NSC 19893) Therapy of Gastrointestinal Cancer¹

Mayo Clinic, Mayo Foundation, Rochester, Minnesota 55901

Thirty-six patients with advanced gastrointestinal carcinoma were treated sequentially with full therapeutic doses of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea followed by 5-fluorouracil. 5-Fluorouracil could be safely administered at 6 weeks although patients still demonstrated peripheral hematological depression secondary to the earlier 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea therapy. Of the 36 patients, 8.3% showed an objective response to 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea therapy. Of the 21 patients who were able to receive sequential 5-fluorouracil, 19% showed objective response. Only 8.3% of all patients entered into this trial showed objective response after completion of the sequential therapy, and this program must be judged as ineffective treatment for gastrointestinal cancer.

¹ Supported by Grant NIH 70-2066 from the National Cancer Institute, NIH, Bethesda, Md.

Received 2/14/72. Accepted 3/ 7/72.